Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: Study of ubiquitin-specific protease 7 inhibitors reveals a different mechanism of action vs. MDM2 inhibitors and shows anti-cancer activity in pre-clinical in vitro and in vivo models of myeloma.”
Proceed to the article.
Source: Robert Orlowski/X